Scancell (LON:SCLP) Trading 29.8% Higher - Still a Buy?

Scancell Holdings plc (LON:SCLP - Get Free Report)'s stock price rose 29.8% during mid-day trading on Monday . The stock traded as high as GBX 11.38 ($0.15) and last traded at GBX 11 ($0.15). Approximately 10,537,342 shares were traded during trading, an increase of 1,073% from the average daily volume of 897,982 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Price Performance

The company has a market cap of £109.27 million, a P/E ratio of -16.18 and a beta of 0.35. The stock has a 50-day simple moving average of GBX 8.58 and a 200 day simple moving average of GBX 10.79. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42.

Scancell (LON:SCLP - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share (EPS) for the quarter. On average, equities analysts expect that Scancell Holdings plc will post -2.5361112 EPS for the current year.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.